Unravelling homologous recombination repair deficiency and therapeutic opportunities in soft tissue and bone sarcoma

Defects in homologous recombination repair (HRR) in tumors correlate with poor prognosis and metastases development. Determining HRR deficiency (HRD) is of major clinical relevance as it is associated with therapeutic vulnerabilities and remains poorly investigated in sarcoma. Here, we show that specific sarcoma entities exhibit high levels of genomic instability signatures and molecular alterations in HRR genes, while harboring a complex pattern of chromosomal instability. Furthermore, sarcomas carrying HRDness traits exhibit a distinct SARC-HRD transcriptional signature that predicts PARP inhibitor sensitivity in patient-derived sarcoma cells. Concomitantly, HRDhigh sarcoma cells lack RAD51 nuclear foci formation upon DNA damage, further evidencing defects in HRR. We further identify the WEE1 kinase as a therapeutic vulnerability for sarcomas with HRDness and demonstrate the clinical benefit of combining DNA damaging agents and inhibitors of DNA repair pathways ex vivo and in the clinic. In summary, we provide a personalized oncological approach to treat sarcoma patients successfully.

[1]  Lara Planas-Paz,et al.  Addressing Modern Diagnostic Pathology for Patient-Derived Soft Tissue Sarcosphere Models in the Era of Functional Precision Oncology. , 2023, Laboratory investigation; a journal of technical methods and pathology.

[2]  Lara Planas-Paz,et al.  Establishment, characterization and functional testing of two novel ex vivo extraskeletal myxoid chondrosarcoma (EMC) cell models , 2022, Human Cell.

[3]  Narasimhan P. Agaram,et al.  Clinical genomic profiling in the management of patients with soft tissue and bone sarcoma , 2022, Nature Communications.

[4]  E. Cuppen,et al.  MutationalPatterns: the one stop shop for the analysis of mutational processes , 2022, BMC Genomics.

[5]  Narasimhan P. Agaram,et al.  Clinical sequencing of soft tissue and bone sarcomas delineates diverse genomic landscapes and potential therapeutic targets , 2021, Nature Communications.

[6]  David T. W. Jones,et al.  DNA methylation-based classifier and gene expression signatures detect BRCAness in osteosarcoma , 2021, PLoS Comput. Biol..

[7]  Ting Chen,et al.  A transcriptional signature detects homologous recombination deficiency in pancreatic cancer at the individual level , 2021, Molecular Therapy. Nucleic Acids.

[8]  L. Kauppi,et al.  Targeting DNA Homologous Repair Proficiency With Concomitant Topoisomerase II and c-Abl Inhibition , 2021, Frontiers in Oncology.

[9]  Brian J. Stevenson,et al.  Cell-autonomous inflammation of BRCA1-deficient ovarian cancers drives both tumor-intrinsic immunoreactivity and immune resistance via STING , 2021, Cell reports.

[10]  H. Chung,et al.  Classification of High-Grade Serous Ovarian Carcinoma by Epithelial-to-Mesenchymal Transition Signature and Homologous Recombination Repair Genes , 2021, Genes.

[11]  Qi Liu,et al.  MCM4 Is a Novel Biomarker Associated With Genomic Instability, BRCAness Phenotype, and Therapeutic Potentials in Soft-Tissue Sarcoma , 2021, Frontiers in Cell and Developmental Biology.

[12]  Jing Tang,et al.  SynergyFinder Plus: Toward Better Interpretation and Annotation of Drug Combination Screening Datasets , 2021, bioRxiv.

[13]  G. Schwartz,et al.  Homologous recombination repair deficiency as a therapeutic target in sarcoma. , 2020, Seminars in oncology.

[14]  J. Martín-Broto,et al.  Sarcoma stratification by combined pH2AX and MAP17 (PDZK1IP1) levels for a better outcome on doxorubicin plus olaparib treatment , 2020, Signal Transduction and Targeted Therapy.

[15]  K. Kang,et al.  Significance of Tumor Mutation Burden in Immune Infiltration and Prognosis in Cutaneous Melanoma , 2020, Frontiers in Oncology.

[16]  R. Lothe,et al.  Molecular correlates of sensitivity to PARP inhibition beyond homologous recombination deficiency in pre-clinical models of colorectal cancer point to wild-type TP53 activity , 2020, EBioMedicine.

[17]  Dung-Fang Lee,et al.  Molecular signatures of BRCAness analysis identifies PARP inhibitor Niraparib as a novel targeted therapeutic strategy for soft tissue Sarcomas , 2020, Theranostics.

[18]  Y. Tao,et al.  Regulating tumor suppressor genes: post-translational modifications , 2020, Signal Transduction and Targeted Therapy.

[19]  M. Dowsett,et al.  Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer , 2020, Nature Communications.

[20]  P. Zhou,et al.  DNA damage response signaling pathways and targets for radiotherapy sensitization in cancer , 2020, Signal Transduction and Targeted Therapy.

[21]  P. Tsagozis,et al.  Multidisciplinary treatment of soft tissue sarcomas: An update , 2020, World journal of clinical oncology.

[22]  N. Matsumura,et al.  Homologous recombination deficiency status-based classification of high-grade serous ovarian carcinoma , 2020, Scientific Reports.

[23]  J. Martens,et al.  Pan-cancer landscape of homologous recombination deficiency , 2020, Nature Communications.

[24]  M. Fassan,et al.  Tumor mutation burden: from comprehensive mutational screening to the clinic , 2019, Cancer Cell International.

[25]  M. Seetharam,et al.  First-Line Therapy for Metastatic Soft Tissue Sarcoma , 2019, Current Treatment Options in Oncology.

[26]  A. Toland,et al.  BRCA1/2 Functional Loss Defines a Targetable Subset in Leiomyosarcoma. , 2019, The oncologist.

[27]  H. You,et al.  Integrated molecular characterization of adult soft tissue sarcoma for therapeutic targets , 2018, BMC Medical Genetics.

[28]  C. Caldas,et al.  A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation , 2018, EMBO molecular medicine.

[29]  Yassen Assenov,et al.  Maftools: efficient and comprehensive analysis of somatic variants in cancer , 2018, Genome research.

[30]  S. Vacher,et al.  Inhibition of mTOR downregulates expression of DNA repair proteins and is highly efficient against BRCA2-mutated breast cancer in combination to PARP inhibition , 2018, Oncotarget.

[31]  Nicolai J. Birkbak,et al.  Migrating the SNP array-based homologous recombination deficiency measures to next generation sequencing data of breast cancer , 2018, npj Breast Cancer.

[32]  Peter J. Park,et al.  Comprehensive analysis of chromothripsis in 2,658 human cancers using whole-genome sequencing , 2018, bioRxiv.

[33]  Aparna Gorthi,et al.  Ewing sarcoma fusion oncogene: At the crossroads of transcription and DNA damage response , 2018, Molecular & cellular oncology.

[34]  K. Thiel,et al.  AZD1775 Increases Sensitivity to Olaparib and Gemcitabine in Cancer Cells with p53 Mutations , 2018, Cancers.

[35]  P. Kristel,et al.  RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[36]  Michael T. Zimmermann,et al.  Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas , 2018, Cell reports.

[37]  K. Stegmaier,et al.  EWS–FLI1 increases transcription to cause R-loops and block BRCA1 repair in Ewing sarcoma , 2018, Nature.

[38]  Samuel F. Bakhoum,et al.  Chromosomal instability drives metastasis through a cytosolic DNA response , 2017, Nature.

[39]  B. Gilks,et al.  Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes , 2015, British Journal of Cancer.

[40]  Katharina I. Deeg,et al.  Integrative genomic and transcriptomic analysis of leiomyosarcoma , 2018, Nature Communications.

[41]  Steven J. M. Jones,et al.  Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue Sarcomas , 2017, Cell.

[42]  J. Mora,et al.  Correction: The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin , 2017, Oncotarget.

[43]  B. Pasini,et al.  PARP1 expression drives the synergistic antitumor activity of trabectedin and PARP1 inhibitors in sarcoma preclinical models , 2017, Molecular Cancer.

[44]  Charles Swanton,et al.  Metastasis as an evolutionary process , 2016, Science.

[45]  Alan Ashworth,et al.  BRCAness revisited , 2016, Nature Reviews Cancer.

[46]  J. Mesirov,et al.  The Molecular Signatures Database Hallmark Gene Set Collection , 2015 .

[47]  Peter J. Campbell,et al.  Chromothripsis and Kataegis Induced by Telomere Crisis , 2015, Cell.

[48]  Florian Engert,et al.  Exome sequencing of osteosarcoma reveals mutation signatures reminiscent of BRCA deficiency , 2015, Nature Communications.

[49]  Nicolai J. Birkbak,et al.  Pan-cancer analysis of genomic scar signatures associated with homologous recombination deficiency suggests novel indications for existing cancer drugs , 2015, Biomarker Research.

[50]  M. Piccart,et al.  An update on PARP inhibitors—moving to the adjuvant setting , 2015, Nature Reviews Clinical Oncology.

[51]  W. Huber,et al.  Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 , 2014, Genome Biology.

[52]  Khin Thway,et al.  Systemic treatment of soft-tissue sarcoma—gold standard and novel therapies , 2014, Nature Reviews Clinical Oncology.

[53]  David T. W. Jones,et al.  Signatures of mutational processes in human cancer , 2013, Nature.

[54]  G. Mills,et al.  Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer , 2012, British Journal of Cancer.

[55]  Steven J. M. Jones,et al.  Comprehensive molecular characterization of human colon and rectal cancer , 2012, Nature.

[56]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumors , 2012, Nature.

[57]  A. Børresen-Dale,et al.  Mutational Processes Molding the Genomes of 21 Breast Cancers , 2012, Cell.

[58]  Guangchuang Yu,et al.  clusterProfiler: an R package for comparing biological themes among gene clusters. , 2012, Omics : a journal of integrative biology.

[59]  R. Freire,et al.  Novel insights into maintaining genomic integrity: Wee1 regulating Mus81/Eme1 , 2011, Cell Division.

[60]  R. Medema,et al.  Wee1 controls genomic stability during replication by regulating the Mus81-Eme1 endonuclease , 2011, The Journal of cell biology.

[61]  Benjamin J. Raphael,et al.  Integrated Genomic Analyses of Ovarian Carcinoma , 2011, Nature.

[62]  A. El-Osta,et al.  γH2AX: a sensitive molecular marker of DNA damage and repair , 2010, Leukemia.

[63]  T. Halazonetis,et al.  Genomic instability — an evolving hallmark of cancer , 2010, Nature Reviews Molecular Cell Biology.

[64]  J. Coindre,et al.  Well-differentiated and dedifferentiated liposarcomas , 2010, Virchows Archiv.

[65]  Wolf-Dietrich Heyer,et al.  Homologous recombination in DNA repair and DNA damage tolerance , 2008, Cell Research.

[66]  Alan Ashworth,et al.  Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy , 2005, Nature.

[67]  Jeremy M. Stark,et al.  Rad51 overexpression promotes alternative double-strand break repair pathways and genome instability , 2004, Oncogene.

[68]  D. Ward,et al.  Sequestration of Mammalian Rad51-Recombination Protein into Micronuclei , 1999, The Journal of cell biology.